Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it has bought back a total of 4,892,629 securities prior to the previous day and an additional 300,000 securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates within the healthcare industry, focusing on providing pathology services. The company offers a range of diagnostic services and is listed on the Australian Securities Exchange under the code ACL.
Average Trading Volume: 1,021,122
Technical Sentiment Signal: Sell
Current Market Cap: A$614.9M
See more data about ACL stock on TipRanks’ Stock Analysis page.